gas and tirzepatide Not Pooping on Tirzepatide: Causes Management Strategies Tirzepatide Side Effects: Common, Severe,

Results from recent trials have demonstrated notably greater reductions in body weight, as illustrated below in the SURMOUNT-3 Phase 3 trial with 25% weight reduction among subjects with GLP-1/GIP and engaged in intensive lifestyle intervention

In accepting the FDAs motion, U.S

Patients with CKD may require potassium restriction rather than supplementation, highlighting the importance of personalised nutritional guidance from a healthcare professional

Insulin-like growth factor in cancer: New perspectives (review)

According to the SmPC, if a patient does not tolerate a dose increase, delaying the increase by an additional 4 weeks can be considered